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INTRODUCTION
Coronary artery disease (CAD) is still highly prevalent; it is
the main cause of mortality worldwide and a major burden
on public health (Leal et al., 2006). According to global and
regional projections of mortality, CAD will remain the lead-
ing cause of death for the next 20 years (Mathers and Lon-
car, 2006). Latvian statistical data (Anonîms, 2008) indicate
that mortality from cardiovascular diseases in Latvia is
higher than the average in the European Union. Due to high
prevalence of CAD, Latvia belongs to ill-disposed regions
(Anonyous, 2004). Stable angina pectoris is one of the most
common presentations of CAD. In spite of recent advances,
mainly in terms of secondary prevention, chronic stable an-
gina remains a major public health concern and its manage-
ment continues to be a challenge.
Heart rate (HR) plays a major role in pathophysiology of
CAD. An increase of HR negatively affects both compo-
nents of the myocardial oxygen balance: increases oxygen
consumption and decreases oxygen supply. In patients with
stable CAD most episodes of myocardial ischemia are asso-
ciated with an increase in HR (Deedwania and Carbajal,
1992; Hinderliter et al., 1991; Panza et al., 1992). The pos-
sibility of developing ischemia is proportional to the value
and duration of the HR increase (Andrews et al., 1993).
Several epidemiological studies suggest that high HR is as-
sociated with increased total as well as cardiovascular (CV)
mortality. This association has been proved not only in pa-
tients with CAD (Diaz et al., 2005; Palatini, 2005) but also
in the general population (Benetos et al., 1999; Menotti et
al., 2001) and various patient populations (Fox et al., 2007),
such as patients after myocardial infarction (Disegni et al.,
1995; Aronow et al., 1996; Futterman and Lemberg, 1999)
and arterial hypertension (Gillman et al., 1993; Palatini et
al., 1999; King et al., 2006; Palatini et al., 2006). The prog-
nostic value of increased resting HR in stable CAD patients
with left ventricular dysfunction has been confirmed in a
prospective way by analysis of a large cohort from the pla-
cebo arm of the BEAUTIFUL trial. The BEAUTIFUL study
proved that HR  70 beats per minute (bpm) significantly
increases cardiovascular (CV) risk in CAD patients (Fox et
al., 2008).
Based on a large body of evidence, high HR as an inde-
pendent CV risk factor has been included in the latest Euro-
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The aim of the REALITY Latvia survey was to accumulate information about treated stable angina
outpatients regarding their characteristics, heart rate (HR), treatment, and quality of life. Thirty
cardiologists were involved with 1–15 patients each. In total, data about 300 patients were ob-
tained. Patients were examined and questioned during one visit. A high HR was defined above 70
beats per minute (bpm), in accordance to recent evidence. Mean HR was 70.3 ± 11.3 bpm and
45% of patients had HR above 70 bpm. The opinion of practitioners regarding HR differed. For
example, a HR level within the range 70–80 bpm was perceived by cardiologists as “normal”,
“borderline high” and “high”. The mean target HR that physicians wanted to achieve was 60.1 ±
4.7 bpm. Beta blockers were used in 91% of cases. The more widely used beta blockers were
metoprolol (47%) and bisoprolol (35%) in mean daily doses 69.7 ± 30.1 mg and 5.3 ± 2.0 mg, re-
spectively. REALITY Latvia data suggest that, despite wide use of beta blockers, HR control in
stable angina patients is insufficient. This is caused by insufficient understanding of HR as a
treatment target by physicians and use of beta blockers in suboptimal dosages.
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pean and Latvian guidelines on CV disease prevention
(Çrglis u.c., 2007; Graham et al., 2007)
Consistent with understanding of the importance of HR in
the pathophysiology of CAD, HR reduction should be an
important therapeutic target for angina management. How-
ever, despite the fact that HR is one of the most frequently
assessed clinical parameters, there is lack of information
about the HR level in clinical practice, particularly in outpa-
tients. It is also not known what proportion of treated outpa-
tients have increased HR, how practitioners evaluate HR,
when do they plan to decrease HR and what is the prefer-
able (target) HR they want to achieve.
The aim of the REALITY Latvia survey was to characterise
outpatients with stable angina, to clarify the level of heart
rate in this population, to describe current treatment and to
evaluate the influence of angina symptoms on everyday ac-
tivities and quality of life.
MATERIALS AND METODS
300 outpatients with treated stable angina were included in
this observational survey during the period from March un-
til May 2006. Thirty cardiologists working in Latvia partici-
pated in the survey and included 1–15 patients each. There
were no exclusion criteria.
Data were collected during one visit and a case report form
for each included patient was filled.
The case report form contained six parts:
1. Demographic data.
2. Physical examination (including measurement of HR).
After ten minutes of rest, HR was measured in sitting posi-
tion by pulse palpation for 1 minute. Additionally, there
were three questions for practitioners: how the physician
evaluates the level of measured HR (as “normal”, “border-
line high” or “high”); does the practitioner plan to decrease
HR, and which target HR he/she is planning to achieve?
3. Symptoms of angina (mean number of attacks and con-
sumption of short-acting nitrates, grade of angina pain ac-
cording to Canadian Cardiovascular Society classification).
4. Medical history (life style, history of CAD, previous drug
treatment, information regarding invasive treatment of
CAD, concomitant diseases).
5. Drug treatment of stable angina (including current treat-
ment (antitrombotic agents, antianginal agents, lipid-
lowering drugs, angiotensin-converting enzyme inhibitors
(ACEI) etc. together with generic names of agents, dosages
and duration of treatment).
6. Influence of angina symptoms on everyday activity and
quality of life. This part included four questions about the
influence of angina symptoms on everyday activity, emo-
tional comfort of patient and level of satisfaction with cur-
rent treatment.
High HR was defined as above 70 (bpm), in accordance to
recent evidence (Fox et al., 2008).
Data were processed using methods of descriptive statistics
and analysed differences by using the Statistical Package
for the Social Sciences (SPSS), version 15.0.
RESULTS
Characteristics of patients. Mean age of patients (n = 300)
was 65 ± 9 years and 191 (63.7%) were men. Mean body
weight in men was 86.4 ± 13.4 kg, in women: 77.5 ± 13.3
kg. Mean height in men was 183.1 ± 7.9 cm, in women:
163.5 ± 8.0 cm. Mean body mass index was 28 ± 4 kg/m2.
Forty seven (16%) patients were smokers (mean number of
cigarettes per day: 15.0 ± 9.4, mean duration of smoking:
27.8 ± 11.6 years). Forty eight (16%) of the patients were
previous smokers (mean number of previously smoked
cigarettes per day: 16.6 ± 8.4, mean duration of previous
smoking: 23.3 ± 10.0 years, mean period after stopping
smoking: 8.4 ± 7.5 years).
The most frequent concomitant diseases were hypertension
and heart failure: 67% and 54%, respectively (Table 1).
The mean level of total cholesterol was 5.4 ± 1.3 mmol/l,
low density lipoprotein cholesterol: 3.2 ± 1.1 mmol/l, high
density lipoprotein cholesterol: 1.3 ± 0.4 mmol/l, and tri-
glycerides: 1.8 ± 1.0 mmol/l. Prevalence of different grades
of angina pain, according to the Canadian Cardiovascular
Society classification, was as follows: class I — 18%, class
II — 47%, class III — 31%, class IV — 3% of patients.
History of myocardial infarction, previous percutaneous
coronary intervention and previous coronary artery bypass
graft surgery was positive in 144 (48%), 119 (40%) and 36
(12%) patients, respectively.
Heart rate. Mean HR was 70.3 ± 11.3 (bpm). In men HR
was 70.0 ± 11.8, in women: 70.8 ± 10.2 bpm (P > 0.05).
The distribution of HR in the study population is shown in
Figure 1.
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T a b l e 1
THE PREVALENCE OF CONCOMITANT DISEASE
Disease Prevalence n (%)
Hypertension: (systolic pressure > 140 mm Hg, or dia-





Chronic obstructive pulmonal disease
Depression
Erectile dysfunction (if men)
Heart failure
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After comparison of HR levels in different age groups
(30–39, 40–49, 50–59, 60–69, 70–79, above 80 years), no
significant differences were found. In patients with current
angina symptoms (n = 267) HR level was higher than in pa-
tients without angina symptoms (n = 25): 70.6 ± 11.2 bpm
vs 67.9 ± 11.2 bpm, but the difference was not significant
(P > 0.05). Patients with angina symptoms at rest (n = 50)
had significantly higher HR than those who did not have an-
gina at rest (n = 222): 73.6 ± 13.9 bpm vs 69.2 ± 10.6 bpm
(P = 0.01).
In 135 (45%) of patients the HR level was above 70 bpm
and in 36 (12%) above 82 bpm. The HR level was signifi-
cantly higher in patients for whom it was planned to de-
crease in comparison with those for whom a HR decrease
was not planned (78.5 ± 9.2 bpm vs 62.6 ± 6.7 bpm (P =
0.001). Practitioners had planned to decrease the HR level
in 114 patients with HR above 70 bpm (84.4% of all pa-
tients with HR above 70 bpm). However, physicians were
not planning to decrease HR in 35% of patients with HR
within the range 71–76 bpm and in 6% of patients with HR
within the range 77– 82 bpm. The target HR (in cases where
cardiologists were planning to decrease HR) was 60.1 ± 4.7
bpm, with a slight variation between groups of different HR
levels (Table 2).
The HR breakdown in three subjective levels: “high”, “bor-
derline high” and “normal” (interpretation of physicians)
showed that HR as “normal” was assessed in a total of 164
cases and in 25 cases when HR was above 70 bpm: in 20
(12%) cases when HR was within the range 71–76 bpm and
in five (3%) cases when HR was within the range 77–82
bpm (Table 3). Mean HR in the subjective levels “normal”,
“borderline high”, and “high” was 63 ± 7 bpm, 74 ± 7 bpm
and 85 ± 9 bpm, respectively.
An HR within the range 70–80 bpm was in many cases as-
sessed by cardiologists as “normal”, “borderline high” and
also as “high” (Fig. 2).
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T a b l e 2
HEART RATE BREAKDOWN IN TOTAL POPULATION, PROPORTION OF PATIENTS WITH PLANNED DECREASE OF HEART RATE AND
CORRESPONDING TARGET HEART RATE
≤ 62 bpm 63–70 bpm 71–76 bpm 77–82 bpm 82 bpm
n % n % n % n % n %
Total population, % (n = 300) 89 30 76 25 51 17 48 16 36 12
Planned to decrease HR (% from respective subgroup) 2 2 29 38 33 65 45 94 36 100
Target HR, mean +SD (if planned to decrease) 60.0 ± 0.0 57.9 ± 3.9 59.9 ± 4.6 60.4 ± 4.1 61.5 ± 5.8





































































Fig. 1. Distribution of heart rate in the study population.
Fig. 2. Subjective interpretation of heart rate by cardiologists.
T a b l e 3


















n % n % n % n % n %
High 57 0 0 1 2 9 16 18 32 29 51
Borderline
high
79 3 4 22 28 22 28 25 32 7 9
Normal 164 86 52 53 32 20 12 5 3 0 0
bpm, beats per minute
Mean = 70.27
Std. Dev. = 11.268
N = 300
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Of all patients with an HR evaluation as „normal”, in 11%
of cases a further decrease of HR was planned. When as-
sessment of HR was „borderline high” or „high”, an HR de-
crease was planned in 89% and 100% of patients, respec-
tively.
Treatment. Treatment of patients with different classes of
drugs is reflected in Figure 3. Regarding antitrombotics,
91% of all patients were treated with aspirin, 16%, with
clopidogrel, and 4%, with oral anticoagulants. 54% of pa-
tients were using isosorbide mononitrate and 12% iso-
sorbide dinitrate. 47% of patients were receiving beta
blocker metoprolol, 35% bisoprolol, 4% carvedilol, 1%
atenolol and 4% — other beta blocker. Of the calcium chan-
nel blockers the most frequently used was amlodipin (48%
of all patients) and only 9% from patients were using other
calcium channel blockers. Non dihidropiridine calcium
channel blockers were used only by five patients (1%). Of
statins the most frequently used was atorvastatin (72%) and
of ACEI — perindopril (51%). Metabolic agent trimetazidin
was used in 26% of cases.
Long-acting nitrates were less used in younger patients < 50
years old than in elderly patients ≥ 70 years old (21% and
79%, respectively). The same tendency was observed with
beta blockers: 84% in group of patients younger than 50
years and 79% in patients who were ≥ 70 years old (Table
4).
Analysis of treatment according to angina status (Canadian
Cardiovascular Society classification — class I to IV)
showed increased usage of long acting nitrates (24%, 68%,
83%, 100% in class I, II, III, IV, respectively), calcium an-
tagonists (52%, 56%, 60%, 44% in class I, II, III, IV respec-
tively) and metabolic agent trimetazidin (22%, 27%, 25%,
44% in class I, II, III, IV, respectively) with severity of an-
gina symptoms.
Analysis of treatment according to HR level showed, that
usage of beta blockers in groups of patients with different
HR level was from 89% of cases in group with HR < 63
bpm to 94% of cases in patients with HR 82 (see Fig. 4),
but the differences between groups were not significant
(P > 0.05).
Mean HR did not differ significantly in patients with or
without prescribed beta blockers, and target HR (60.1 ± 4.7
bpm) was not achieved in either group. There where slightly
more patients with a planned decrease of HR in the group
using beta blockers (49%) in comparison with patients not
using beta blockers (42%), but the difference was not sig-
nificant (P > 0.05). The average time of using beta blockers
was 28 months for metoprolol, 20 months for bisoprolol and
19 months for other beta blockers. HR did not differ statisti-
cally significantly according to usage of different beta
blockers.




























































T a b l e 4











n % n % n % n % n %
Antitrombotic agents 289 96 18 95 59 95 103 97 105 96
Long-acting nitrates 197 66 4 21 41 66 64 60 86 79
Beta blockers 274 91 16 84 60 97 95 90 99 91
Calcium channel blockers 170 57 9 47 39 63 65 61 55 50
Lipid-lowering drugs 250 83 16 84 55 89 89 84 87 80
ACEI 246 82 15 79 52 84 83 78 94 86
ARB 9 3 0 0 2 3 2 2 4 4
Trimetazidin 77 26 7 37 14 23 30 28 25 23
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers
Fig. 3. Treatment of patients with different
classes of drugs. ACEI, angiotensin-converting
enzyme inhibitors
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Average daily doses of different beta blockers in the total
population and according to concomitant diseases are sum-
marized in Table 5. There is a tendency that co-morbidities
considered as contraindications for usage of beta blockers
or symptoms of intolerance are not associated with smaller
doses in comparison with those used in the total population.
The dose of metoprolol was significantly (P < 0.05) higher
in groups of patients with higher HR. The same tendency
was not observed for bisoprolol. Irrespectively of how phy-
sicians assessed HR (“normal”, “borderline high” or “high”)
the frequency of usage of beta blockers did not differ signif-
icantly. However, doses of beta blockers — higher subjec-
tive levels of HR were associated with significantly (P <
0.01) higher dose of metoprolol (63 ± 28 mg if level was
“normal”, 70 ± 29 mg if level was “borderline high” and 84
± 32 mg if the level was considered as “high”). Doses of
bisoprolol did not change according to the subjective level
of HR.
The beta blocking agent used was switched within the last
12 months in 33 (12%) patients of all 274 patients using
beta blockers. In eight patients the change was made due to
intolerance: bradicardia (3), exacerbation of bronchial
asthma or chronic obstructive pulmonal disease (2), dizzi-
ness and fatigue (2), prolonged QT (1) and in 19 patients
due to other reasons: insufficient efficiency (13), decision of
doctor (5), desire of patient (2). Nine (35%) patients from
all 26 not using beta blockers were using them previously,
but stopped later. Of them, four cases were due to side ef-
fects: erectile dysfunction (1), bradicardia (2), exacerbation
of bronchial asthma (1), and five — due to other reasons:
decision of doctor (3), desire of patient (2).
155 (52%) of REALITY Latvia patients were post re-
vascularization cases. Of these, 82 cases (65% of all
revascularised patients) symptoms of angina were persisting
and in 125 cases (81% of all revasularised patients) treat-
ment with antiangial agents was needed.
Influence of angina on quality of life. The most frequent
answers of patients to the question about influence of an-
gina symptoms on everyday activities were: “somewhat
limited” — 28% and “a little limited” — 29%. On the ques-
tion about influence of angina on enjoinment of life during
the last month, 27% of patients answered “somewhat lim-
ited” and 32% “a little limited”. Asked how often they
worry that he/she may have a heart attack, 36% of patients
answered “sometimes” and in 35% cases the answer was
“rarely”. On the question about satisfaction with current
antianginal treatment 26% of patients answered “rather sat-
isfied” and in 39% of cases the answer was “almost satis-
fied” (Fig. 5).
We observed a relationship between HR and the level of
worry about heart attacks. Patients who were more often
worried that he/she may have a heart attack had a higher
heart rate than those who were not worried about attacks
(P < 0.01) (Table 6).
Answers on questions about the influence of angina on
quality of life did not significantly differ in patients not us-
ing beta blockers in comparison with those on beta
blockers. There were also no significant differences in an-
swers on quality of life questions between groups of pa-
tients with different HR level.
DISCUSSION
Characteristics of patients in the REALITY Latvia survey
were typical for CAD in general as the proportion of males
and females, mean age, body mass index, percentage of
smokers and hypertension as the most frequent co-morbid-
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T a b l e 5


















Total population 25.0 ± 0.0 5.3 ± 2.0 17.2 ± 13.5 69.7 ± 30.1
Diabetes mellitus - 6.0 ± 2.2 25.0 ± 21.7 73.4 ± 37.4
Peripheral arterial
disease
- 4.5 ± 3.3 6.25 78.6 ± 26.7
Bronchial asthma - 10.0 - 50.0
COPD - 3.8 ± 1.4 25.0 66.7 ± 28.9
Depression - 5.0 ± 3.5 - 75.0 ± 28.9
Erectile dysfunction - 6.3 ± 5.3 - 80.0 ± 44.7
SD, standard deviation
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Fig. 4. Treatment with beta blockers according to heart rate.
T a b l e 6
HEART RATE ACCORDING TO LEVEL OF WORRY ABOUT HEART
ATTACKS
How often does the patient worry
that he/she may have heart attack?
n HR (bpm)
Mean ± SD
All the time 4 65.5 ± 10.0
Often 59 74.6 ± 12.4
Sometimes 107 70.5 ± 11.0
Rarely 104 68.2 ± 11.1
Never 22 68.3 ± 11.3
SD, standard deviation; bpm, beats per minute
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ity follow the same trends as in trials with participation of
CAD patients (Anonymous, 2008). The data are also com-
parable to the population in the Euro Heart Survey (EHS),
where 156 cardiology clinics participated from 34 countries
with 3031 patients, included on the basis of a new clinical
diagnosis of stable angina by a cardiologist (Daly et al.,
2006).
Our data indicate that stable angina outpatients in Latvia
have a relatively high HR despite widely used treatment
with beta blockers. Almost half of patients (45%) have HR
at rest above 70 bpm, which is the level, which is associated
with significantly higher CV risk (Fox et al., 2008). These
data are in line with the global situation in Europe. Investi-
gators of the EHS survey showed, that despite treatment,
53% of angina patients had a HR higher than 70 bpm (Daly
et al., 2008). Even if mean HR in REALITY Latvia was
lower than in EHS (70 bpm vs 73 bpm) and the proportion
of patients with high HR (above 70 bpm) was slightly lower
than in EHS, the situation with perception of HR as a major
treatment target in management of stable angina by cardiol-
ogists in Latvia does not seem very optimistic. Our data
show a big gap (10 bpm) between the mean actual HR of
the patients and mean target HR that cardiologists want to
achieve when planning to decrease it. Taking into account
that patients in the REALITY Latvia population are already
treated by cardiologists, this difference is very worrying. In
real life angina patients are frequently treated by general
practitioners. Understanding the role of HR in patho-
physiology and prognosis of CAD can be significantly
weaker among general practitioners than among cardiolo-
gists, and therefore, HR control in patients treated by gen-
eral practitioners can be even worse.
According to our data, physicians do not have a clear view,
which exactly level of HR should be considered as high for
CAD patients and should be treated specifically to decrease
it. An HR between 70 and 80 can be evaluated by cardiolo-
gists as “normal”, “borderline high” or “high”. However,
perception of a certain level of HR as high seems crucial to
induce specific treatment for reduction of HR. Cardiologists
did not plan to reduce HR in 41% of cases when HR was
above 70 bpm and in 6% of cases when HR was already
above 77 bpm. However, when evaluation of the HR was
regarded as “high”, decision of reduction of HR is taken in
100% of cases.
These findings strongly demonstrate that not HR per se (be-
ing high or not) determines decision of practitioners to re-
duce it, but perception of HR as high does. Hence, in order
to have better HR control in CAD patients, certain changes
in the perception of physicians should take place. Taking
into account evidence regarding increased cardiovascular
risk in CAD patients with HR ≥ 70 bpm (Fox, 2008), pa-
tients could significantly benefit if practitioners consider
HR above 70 bpm as high.
In general, patients in the REALITY Latvia survey were
better treated in comparison with the population in EHS. In
REALITY, a larger proportion of patients were using aspi-
rin (91% vs 78%), other antiplatelets (20% vs 9%), statins
(83% vs 48%), beta blockers (91% vs 67%), ACEI (82% vs
40%) than in EHS (Daly, 2005). Wider use of beta blockers
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Fig. 5. Answers of patients on questions about influence of angina on quality of life.
Are yo r e li ited due to
angina sy pto s?
How often do you worry that you may have
a heart attack?
Was enj ent of life limited due to angina
sy to s during last month?
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in REALITY Latvia was associated with lower mean HR
and lower proportion of patients with HR above 70 bpm
than in EHS. The usage of preventive treatment in REAL-
ITY Latvia was high and comparable with that in large
CAD trials where patients used optimal basic therapy —
BEAUTIFUL, EUROPA, COURAGE (Anonymous, 2003;
2008; Boden, 2007; Anonymous, 2008). This indicates a fa-
vourable trend in following guidelines and considering car-
diovascular prevention by treating angina patients.
Despite very wide usage of beta blockers in the REALITY
Latvia population (91%), doses of beta blockers were rela-
tively low in comparison with those suggested by clinical
trials. This is not unique to Latvia as meta-analysis from
55 315 patients after myocardial infarction (Gislason, 2006)
showed, that under-dosing of beta blockers is typical in the
community (patients were using 50% or less of the dosages
used in clinical trials) and associated with poor long-term
compliance.
Of note, 52% of REALITY patients were previously
revascularised and most of them were also using antianginal
agents. This observation underlines the necessity for phar-
macological treatment (preventive, less antianginal) after
revascularisation.
We found that patients with current symptoms of angina at
rest had significantly higher HR than those without, but the
difference between higher HR in patients with current an-
gina symptoms in comparison with those without symptoms
did not reach statistical significance. This could be ex-
plained by a very small number of patients without current
symptoms (n = 25) in the survey.
Quality of life analysis showed that stable angina patients in
Latvia are relatively satisfied with their quality of life and
treatment. The majority of patients pointed out that their
daily life and enjoyment of life was slightly limited due to
angina symptoms and agreed that they are almost satisfied
with their current treatment. The significant relationship be-
tween higher HR in patients who were worried about heart
attacks, in comparison with HR in less worried patients,
proves potential of high HR to influence quality of life neg-
atively.
In our survey data were collected only at one visit. Together
with a relatively small number of patients this limitation for
interpretation of the results should be acknowledged. To un-
derstand how HR evaluation by practitioners and how the
decisions made regarding HR reduction influence further
treatment, symptoms of angina and quality of life, longer
studies with follow-up period are needed.
In conclusion, the results of the REALITY Latvia survey
suggest that stable angina outpatients managed by cardiolo-
gists in Latvia are relatively well treated. Despite a high
proportion of patients using beta blockers, HR control is in-
sufficient. There is big gap (10 bpm) between mean actual
HR of the patients and mean target HR that doctors want to
achieve when planning to decrease it. HR above 70 bpm,
which is the level with proved increase of CV risk in CAD
patients, was observed in a substantial proportion of treated
angina patients. It was mainly due to suboptimal use of
medication to achieve the target HR. Perception of a certain
level of HR as high is crucial for making decision about a
further HR decrease, but practitioners do not have a com-
mon view about the exact level of HR, which should be
considered as high. Therefore, much remains to be done in
order to establish HR as a treatment target, to increase
awareness of benefits from HR reduction, and options to
achieve target HR with pharmacological treatment.
ACNOWLEDGMENTS
This survey was supported by Servier. REALITY Latvia Na-
tional Coordinator Andrejs Çrglis, investigators Gustavs
Latkovskis, Iveta Mintâle and authors are grateful to all
REALITY investigators: Vçsma Ârgale, Anita Baika,
Ludmila Basina, Solveiga Budrçvièa, Gaïina Dormi-
dontova, Veronika Eèina, Arèils Gersamija, Silvija Han-
sone, Inga Jasinkevièa, Maija Keiða, Mâra Klovâne, Ausma
Kondratovièa, Lîga, Liepa, Ilga Lûse, Lija Mora, Nataïja
Pontaga, Ilze Sarmîte Rozentâle, Nadeþda Roþkova, Irçna
Aija Rubîne, Mârîte Skulte, Alla Soboïeva, Mâra Stabul-
niece, Iveta Striþko, Larisa Timoòina, Gunta Vçvere, Santa
Viltere, Mâra Vîtola, Ausma Vîva.
REFERENCES
Anonîms (2008). Latvijas veselîbas statistikas gadagrâmata par 2007. gadu
[Annual book of Latvian health statistics about 2007]. Veselîbas statistikas
un medicînas terminoloìiju aìentûra, 2008 (in Latvian).
Anonymous (2003). The European trial on reduction of cardiac events with
perindopril in patients with stable coronary artery disease investgators. Ef-
ficacy of perindopril in reduction of cardiovascular events in stable coro-
nary artery disease: Randomised, duble-blind, placebo controlled,
multicentre trial (the EUROPA study). Lancet, 362, 782–788.
Anonymous (2004). World Health Organization.
https://apps.who.int/infobase/Comparisons.aspx
Anonymous (2008). The BEAUTIFUL Study Group. The BEAUTIFUL
study: Randomized trial of ivabradine in patients with stable coronary ar-
tery disease and left ventricular systolic dysfunction — baseline character-
istics of the study population. Cardiology, 110, 271–282.
Andrews, T.C., Fenton, T., Toyosaki, N., Glasser, S.P., Young, P.M.,
MacCallum, G., Gibson, R.S., Shook, T.L., Stone, P.H. (1993). The An-
gina and Silent Ischemia Study Group (ASIS). Subsets of ambulatory myo-
cardial ischemia based on heart rate activity. Circadian distribution and re-
sponse to anti-ischemic medication. Circulation, 88, 92–100.
Aronow, W.S., Ahn, C., Mercando, A.D., Epstein, S. (1996). Association of
average heart rate on 24-hour ambulatory electrocardiograms with inci-
dence of new coronary events at 48-month follow-up in 1,311 patients
(mean age 81 years) with heart disease and sinus rhythm. Amer. J. Cardiol.,
78(10), 1175–1176.
Benetos, A., Rudnichi, A., Thomas, F., Safar, M., Guize, L. (1999). Influence
of heart rate on mortality in a French population: Role of age, gender and
blood pressure. Hypertension, 33, 44–52.
Boden, W.E., O’Rouke, R., Teo, K.T., Hartigan, P.M., Maron, D.J., Kostuk,
W.I., Knudston, M., Dada, M., Casperson, P., Harris, C.L., Chaitman, B.R.,
Shaw, L., Gosselin, G., Navaz, S., Title, L.M. Gau, G., Blaustein A.S.,
Booth, D.C., Bates, E.R., Spertus, J.A., Berman, D.S., Mancini, J.,
Weintraub, W.S. for the COURAGE Trial Research Group. (2007). Opti-
mal Medical Therapy with or without PCI for Stable Coronary Disease.
200 Proc. Latvian Acad. Sci., Section B, Vol. 64 (2010), No. 5/6.
 - 10.2478/v10046-011-0004-6
Downloaded from De Gruyter Online at 09/12/2016 06:21:53AM
via Cornell University Library and Cornell University Library
New Engl. J. Med., 356. This article (10.1056/NEJMoa070829) was pub-
lished at www.nejm.org on 27 March 2007.
Daly, C.A., Clemens, F., Lopez Sendon, J.L., Tavazzi, L., Boersma, E.,
Danchin, N., Delahaye, F., Gitt, A., Julian, D., Mulcahy, D., Ruzyllo, W.,
Thygesen, K., Verheugt, F., Fox, K.M. (2005). The initial management of
stable angina in Europe, from the Euro Heart Survey: A description of
pharmacological management and revascularization strategies initiated
with the first month of presentation to a cardiologist in the Euro Heart Sur-
vey of Stable Angina. Eur. Heart J., 26, 1011–1022.
Daly, C.A., De Stavola, B., Lopez-Sendon, J.L., Tavazzi, L., Boersma, E.,
Clemens, F., Danchin, N., Delahaye, F., Gitt, A., Julian, D., Mulcahy, D.,
Ruzyllo, W., Thygesen, K., Verheugt, F., Fox, K.M. (2006). Predicting
prognosis in stable angina — results from the Euro Heart Survey of stable
angina: Prospective observational study. BMJ, 332, 262–267.
Daly, C., Tavazzi, L., Fox, K., Euro Heart Survey of Angina Investigators
(2008). Inadequate control of heart rate in patients with stable angina: Re-
sults from the European Heart Survey. Eur. Heart J., 29 (Abstract Supple-
ment), 204.
Deedwania, P.C., Carbajal, E.V. (1992). Role of myocardial oxygen demand
in the pathogenesis of silent ischemia during daily life. Amer. J. Cardiol.,
70, 19F–24F.
Diaz, A., Bourassa, M.G., Guertin, M.C., Tardif, J.C. (2005). Long term
prognostic value of resting heart rate in patients with suspected or proven
coronary artery disease. Eur. Heart J., 26(10), 967–974.
Disegni, E., Goldbourt, U., Reicher-Reiss, H., Kaplinsky, E., Zion, M.,
Boyko, V., Behar, S. and the SPRINT study group (1995). The predictive
value of admission heart rate on mortality in patients with acute myocardial
infarction. J. Clin. Epidemiol., 48, 1197–1205.
Çrglis, A., Kalvelis, A., Lejnieks, A., Dzçrve, V., Latkovskis, G., Mintâle, I.,
Zakke, I., Rasa, I. (2007). Kardiovaskulâro slimîbu (KVS) profilakses
vadlînijas [Guidelines on cardiovascular disease prevention]. Rîga. 45. lpp.
(in Latvian).
Fox, K., Borer, J.S., Camm, A.J., Danchin, N., Ferrari, R., Sendon, J.L.L.,
Steg, P.G., Tardif, J.C., Tavazzi, L., Tendera, M., for a Heart Rate working
Group (2007). Resting heart rate in cardiovascular disease. J. Amer. Coll.
Cardiol., 50, 823–830.
Fox, K., Ford, I., Steg, P.G., Tendera, M., Robertson, M., Ferrari R. (2008).
Heart rate as a prognostic risk factor in patients with coronary artery dis-
ease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup
analysis of a randomised controlled trial. Lancet, 372(9641), 817–821.
Futterman, L.G., Lemberg, L. (1999). Heart rate is a simplistic marker of
mortality in acute myocardial infarction. Amer. J. Crit. Care, 8(3),197-199.
Gillman, M.W., Kannel, W.B., Belanger, A., D’Agostino, R.B. (1993). In-
fluence of heart rate on mortality among persons with hypertension: The
Framingham study. Amer. Heart J., 125(4), 1148–1154.
Gislason, G.H., Rasmussen, J.N., Abildstrom, S.Z., Gadsboll, N., Buch, P.,
Friberg, J., Rasmussen, S., Kober, L., Stender, S., Madsen, M.,
Torp-Pederden, C. (2006). Long term compliance with beta-blockers, an-
giotensin-converting inhiitors, and statins after acute myocardial infarc-
tion. Eur. Heart J., 27, 1153–1158.
Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R.,
Dallongeville, J., De Backer, G., Ebrahim, S., Gjelsvik, B., Herrmann-
Lingen, C., Hoes, A., Humphries, S., Knapton, M., Perk, J., Priori, S.G.,
Pyorala, K., Reiner, Z., Ruilope, L., Sans-Menendez, S., Reimer, V.S.O.,
Weissberg, P., Wood, D., Yarnell, Y., Zamorano, J.L. (2007). European
guidelines on cardiovascular disease prevention in clinical practice: Execu-
tive summary. Eur. Heart J., 28, 2375–2414.
Hinderliter, A., Miller, P., Bragdon, E., Ballenger, M., Sheps, D. (1991).
Myocardial ischemia during daily activities: The importance of increased
oxygen demand. J. Amer. Coll. Cardiol., 18, 405–412.
King, D.E., Everett, C.J., Mainous, A.G., Liszka, H.A. (2006). Long-term
prognostic value of resting heart rate in subjects with prehypertension.
Amer. J. Hypertens., 19(8), 796–800.
Leal, J., Luengo-Fernández, R., Gray, A., Petersen, S., Rayner, M. (2006).
Economic burden of cardiovascular diseases in the enlarged European Un-
ion. Eur. Heart J., 27(13), 1610–1619.
Mathers, C.D., Loncar, D. (2006). Projections of global mortality and buren
of disease from 2002 to 2030. PLoSMed., Nov, 3, e442.
Menotti, A., Mulder, I., Nissinen, A., Giampaoli, S., Feskens, E.J.,
Kromhout, D. (2001) Prevalence of morbidity and multimorbidity in el-
derly male populations and their impact on 10-year all-cause mortality: The
FINE study (Finland, Italy, Netherlands, Elderly). J. Clin. Epidemiol., 54,
680–686.
Palatini, P., Benetos, A., Julius, S. (2006). Impact of increased heart rate on
clinical outcomes in hypertension. Implications for antihypertensive drug
therapy. Drugs, 66, 133–144.
Palatini, P., Casiglia, E., Julius, S., Pessina, A.C. (1999). High heart rate: A
risk factor for cardiovascular death in elderly men. Arch. Intern. Med., 159,
585–592.
Palatini, P. (2005). Heart rate: A strong predictor of mortality in subjects with
coronary artery disease. Eur. Heart J., 26(10), 943–945.
Panza, J.A., Diodati, J.G., Callahan, T.S., Epstein, S.E., Quyyumi, A.A.
(1992). Role of increases in heart rate in determining the occurrence and
frequency of myocardial ischemia during daily life in patients with stable
coronary artery disease. J. Amer. Coll. Cardiol., 20, 1092–1098.
201Proc. Latvian Acad. Sci., Section B, Vol. 64 (2010), No. 5/6.
AMBULATORO STENOKARDIJAS PACIENTU ÂRSTÇÐANAS UN SIRDS RITMA NOVÇROJUMS LATVIJÂ (REALITY LATVIA)
Novçrojuma mçríis bija iegût informâciju par ambulatori ârstçtu stenokardijas pacientu populâciju Latvijâ, noskaidrot pacientu profilu,
sirds ritmu, stabilas stenokardijas ârstçðanas paradumus un pacientu dzîves kvalitâti. Vienas vizîtes ietvaros tika apsekoti un iztaujâti 300
ârstçti stabilas slodzes stenokardijas pacienti. 30 kardiologi katrs ievâca datus par 1–15 pacientiem un aizpildîja gadîjuma ziòojuma
veidlapas. Datu analîzes laikâ, atbilstoði jaunâkajiem zinâtniskajiem atzinumiem par palielinâtu sirdsdarbîbas frekvenci, tika definçts
lîmenis virs 70 ×/min. Vidçjâ sirdsdarbîbas frekvence bija 70,3 ± 11,3 ×/min un 45% pacientu tâ bija virs 70 ×/min. Ârstu viedoklis par
sirdsdarbîbas frekvenci atðíîrâs, piemçram, frekvence starp 70 un 80 tika atzîta gan kâ „normâla”, gan „uz robeþas ar augstu”, gan „augsta”.
Vidçjâ sirdsdarbîbas frekvence, ko ârsti plânoja sasniegt, bija 60,1 ± 4,7 ×/min. Beta blokatori tika lietoti 91% gadîjumu. Bieþâk lietotie
beta blokatori bija metoprolols (47% gadîjumu) un bisoprolols (35% gadîjumu). Vidçjâ dienas deva metoprololam bija 69,7 ± 30,1 mg
dienâ, bisoprololam — 5,3 ± 2,0 mg. Novçrojuma rezultâti ïauj secinât, ka, neraugoties uz plaðu beta blokatoru lietoðanu, sirdsdarbîbas
frekvences kontroles lîmenis ir nepietiekams. Tas skaidrojams ar ârstu nepietiekamo izpratni par sirdsdarbîbas frekvences samazinâðanu kâ
lîdzekli stenokardijas ârstçðanas mçríu sasniegðanai un beta blokatoru lietoðanu salîdzinoði mazâs devâs.
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